Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma von Morschhauser, Franck, Fowler, Nathan H, Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M. Lia, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicolas, Le Gouill, Steven, Pica, Gian M, Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H, Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A

Volltext

Validation study of end-of-life risk prediction model in active chemotherapy patients von Hill, Melinda S., Abdo-Matkiwsky, May D., Biran, Noa, Chatiwala, Jumana, Chen, Aileen L., Childs, Julianne Wilkins, Fitzgerald, Denis, Graham, Deena Mary Atieh, Horkheimer, Ian, Levenbach, Rachel L., McLaughlin, Joseph Francis, Salwitz, Kimberly A., Smith, Frederick P., Tassan, Robert F., Ejumejowo, Akunna J.

Volltext

Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation von Horkheimer, Ian, Quigley, Michael, Zhu, Jiangao, Huang, Xiaopei, Chao, Nelson J., Yang, Yiping

Volltext